-
1
-
-
67649282667
-
-
Guidance for Industry: drug interaction studies - study design, data analysis and implications for dosing and labeling. http://www.fda.gov/cber/ gdlns/interactstud.htm Draft published in September 2006. Last accessed 6 October 2006.
-
Guidance for Industry: drug interaction studies - study design, data analysis and implications for dosing and labeling. http://www.fda.gov/cber/ gdlns/interactstud.htm Draft published in September 2006. Last accessed 6 October 2006.
-
-
-
-
2
-
-
54449098492
-
Preparation of scientific reports on pharmacokinetic drug interaction studies
-
Greenblatt DJ. Preparation of scientific reports on pharmacokinetic drug interaction studies. J Clin Psychopharmacol. 2008;28(4):369-373.
-
(2008)
J Clin Psychopharmacol
, vol.28
, Issue.4
, pp. 369-373
-
-
Greenblatt, D.J.1
-
3
-
-
8044237061
-
Clinical biostatistics I. A new name and some other changes of the guard
-
Feinstein AR. Clinical biostatistics I. A new name and some other changes of the guard. Clin Pharmacol Ther. 1970;11:135-148.
-
(1970)
Clin Pharmacol Ther
, vol.11
, pp. 135-148
-
-
Feinstein, A.R.1
-
5
-
-
0035032568
-
Interindividual variability in inhibition and induction of cytochrome P450 enzymes
-
Lin JH, Lu AYH. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol. 2001;41:535-567.
-
(2001)
Annu Rev Pharmacol Toxicol
, vol.41
, pp. 535-567
-
-
Lin, J.H.1
Lu, A.Y.H.2
-
6
-
-
29544449443
-
Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19
-
de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics. 2006;47(1):75-85.
-
(2006)
Psychosomatics
, vol.47
, Issue.1
, pp. 75-85
-
-
de Leon, J.1
Armstrong, S.C.2
Cozza, K.L.3
-
7
-
-
62449286261
-
DNA microarray technology in the clinical environment: The AmpliChip CYP450 Test for CYP2D6 and CYP2C19 genotyping
-
de Leon J, Susce MT, Johnson M, et al. DNA microarray technology in the clinical environment: the AmpliChip CYP450 Test for CYP2D6 and CYP2C19 genotyping. CNS Spectr. 2009;14(1):19-34.
-
(2009)
CNS Spectr
, vol.14
, Issue.1
, pp. 19-34
-
-
de Leon, J.1
Susce, M.T.2
Johnson, M.3
-
8
-
-
34248597277
-
A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels
-
de Leon J, Susce MT, Pan RM, et al. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry. 2007;40(3):93-102.
-
(2007)
Pharmacopsychiatry
, vol.40
, Issue.3
, pp. 93-102
-
-
de Leon, J.1
Susce, M.T.2
Pan, R.M.3
-
10
-
-
30344457586
-
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
-
Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79(1):103-113.
-
(2006)
Clin Pharmacol Ther
, vol.79
, Issue.1
, pp. 103-113
-
-
Sim, S.C.1
Risinger, C.2
Dahl, M.L.3
-
11
-
-
34248596149
-
The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 and CYP2C19
-
de Leon J. The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 and CYP2C19. J Clin Psychopharmacol. 2007;27(3):241-245.
-
(2007)
J Clin Psychopharmacol
, vol.27
, Issue.3
, pp. 241-245
-
-
de Leon, J.1
-
12
-
-
44849135619
-
Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables
-
Diaz FJ, Santero V, Spina E, et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry. 2008;41(3):81-91.
-
(2008)
Pharmacopsychiatry
, vol.41
, Issue.3
, pp. 81-91
-
-
Diaz, F.J.1
Santero, V.2
Spina, E.3
-
13
-
-
47749087003
-
Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model
-
Botts S, Diaz FJ, Santoro V, et al. Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(6):1453-1458.
-
(2008)
Prog Neuropsychopharmacol Biol Psychiatry
, vol.32
, Issue.6
, pp. 1453-1458
-
-
Botts, S.1
Diaz, F.J.2
Santoro, V.3
-
15
-
-
33845988396
-
Metabolic drug interactions with newer antipsychotics: A comparative review
-
Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007;100(1):4-22.
-
(2007)
Basic Clin Pharmacol Toxicol
, vol.100
, Issue.1
, pp. 4-22
-
-
Spina, E.1
de Leon, J.2
-
16
-
-
0037345011
-
Glucuronidation enzyme genes and psychiatry
-
de Leon J. Glucuronidation enzyme genes and psychiatry. Int J Neuropsychopharmacol. 2003;6(1):57-72.
-
(2003)
Int J Neuropsychopharmacol
, vol.6
, Issue.1
, pp. 57-72
-
-
de Leon, J.1
-
17
-
-
32944471001
-
So many studies, too few subjects: Establishing functional relevance of genetic polymorphisms on pharmacokinetics
-
Williams JA, Johnson K, Paulauskis J, et al. So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics. J Clin Psychopharmacol. 2006;46(3):258-264.
-
(2006)
J Clin Psychopharmacol
, vol.46
, Issue.3
, pp. 258-264
-
-
Williams, J.A.1
Johnson, K.2
Paulauskis, J.3
-
18
-
-
0035103586
-
Fluoxetine pharmacokinetics and effects on CYP2C19 in young and elderly volunteers
-
Harvey AT, Preskorn S. Fluoxetine pharmacokinetics and effects on CYP2C19 in young and elderly volunteers. J Clin Psychopharmacol. 2001;21(2):161-166.
-
(2001)
J Clin Psychopharmacol
, vol.21
, Issue.2
, pp. 161-166
-
-
Harvey, A.T.1
Preskorn, S.2
-
19
-
-
0035195659
-
Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy
-
Brunswick DJ, Amsterdam JD, Fawcett J, et al. Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy. J Clin Psychopharmacol. 2001;21(6):616-618.
-
(2001)
J Clin Psychopharmacol
, vol.21
, Issue.6
, pp. 616-618
-
-
Brunswick, D.J.1
Amsterdam, J.D.2
Fawcett, J.3
-
20
-
-
0031800865
-
A mechanistic approach to antiepileptic drug interactions
-
Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998;32(5):554-563.
-
(1998)
Ann Pharmacother
, vol.32
, Issue.5
, pp. 554-563
-
-
Anderson, G.D.1
-
21
-
-
0842266734
-
Psychopharmacology: Atypical antipsychotic dosing: the effect of co-medication with anticonvulsants
-
de Leon J. Psychopharmacology: atypical antipsychotic dosing: the effect of co-medication with anticonvulsants. Psychiatr Serv. 2004;55(2):125-128.
-
(2004)
Psychiatr Serv
, vol.55
, Issue.2
, pp. 125-128
-
-
de Leon, J.1
-
22
-
-
2442495384
-
Psychopharmacology: Atypical antipsychotic dosing: the effect of smoking and caffeine
-
de Leon J. Psychopharmacology: atypical antipsychotic dosing: the effect of smoking and caffeine. Psychiatr Serv. 2004;55(5):491-493.
-
(2004)
Psychiatr Serv
, vol.55
, Issue.5
, pp. 491-493
-
-
de Leon, J.1
-
23
-
-
0035142323
-
The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine
-
Wong YW, Yeh C, Thyrum PT. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J Clin Psychopharmacol. 2001;21(1):89-93.
-
(2001)
J Clin Psychopharmacol
, vol.21
, Issue.1
, pp. 89-93
-
-
Wong, Y.W.1
Yeh, C.2
Thyrum, P.T.3
-
24
-
-
67649279470
-
-
Astra Zeneca Pharmaceuticals. Seroquel (Quetiapaine Fumarate Tablets): Highlights of Prescribing Information. Wilmington, DE: Astra Zeneca Pharmaceuticals; 2008.
-
Astra Zeneca Pharmaceuticals. Seroquel (Quetiapaine Fumarate Tablets): Highlights of Prescribing Information. Wilmington, DE: Astra Zeneca Pharmaceuticals; 2008.
-
-
-
-
26
-
-
0032807123
-
Possible interaction between warfarin and quetiapine
-
Rogers T, de Leon J, Atcher D. Possible interaction between warfarin and quetiapine. J Clin Psychopharmacol. 1999;19(4):382-383.
-
(1999)
J Clin Psychopharmacol
, vol.19
, Issue.4
, pp. 382-383
-
-
Rogers, T.1
de Leon, J.2
Atcher, D.3
-
27
-
-
67649279469
-
Drug interactions
-
Shorvon S, Perucca E, Engel J, eds, 3rd ed. Oxford: Wiley-Blackwell Publishing Ltd;
-
Spina E. Drug interactions. In: Shorvon S, Perucca E, Engel J, eds. Treatment of Epilepsy. 3rd ed. Oxford: Wiley-Blackwell Publishing Ltd; 2009:361-377.
-
(2009)
Treatment of Epilepsy
, pp. 361-377
-
-
Spina, E.1
-
28
-
-
12844256482
-
Complexity of medication use in the Veterans Affairs healthcare system: Part I: Outpatient use in relation to age and number of prescribers
-
Preskorn SH, Silkey B, Shah R, et al. Complexity of medication use in the Veterans Affairs healthcare system: Part I: Outpatient use in relation to age and number of prescribers. J Psychiatr Pract. 2005;11(1):5-15.
-
(2005)
J Psychiatr Pract
, vol.11
, Issue.1
, pp. 5-15
-
-
Preskorn, S.H.1
Silkey, B.2
Shah, R.3
|